RESUMEN
Improving cell uptake of metal compounds has became an important goal in the field of metal-based anticancer agents. This may combat platinum resistance and side effects seen commonly in current anticancer chemotherapy regimes. Here, we explore a novel degradable ruthenium-albumin hydrogel, which shows strong luminescence for cell imaging and high selectivity for cancer cells versus non-cancer cells. This is an early indication of the possibility of reducing unwanted side effects of metals by using bovine serum albumin hydrogel as a delivery strategy. This work provides a strong basis for development of a new class of metal-based cancer therapeutic agents.
Asunto(s)
Antineoplásicos/farmacología , Complejos de Coordinación/farmacología , Hidrogeles/química , Sustancias Luminiscentes/química , Rutenio/química , Albúmina Sérica Bovina/química , Animales , Antineoplásicos/química , Antineoplásicos/toxicidad , Bovinos , Línea Celular Tumoral , Complejos de Coordinación/química , Complejos de Coordinación/toxicidad , Endopeptidasa K/química , Humanos , Hidrogeles/síntesis química , Hidrogeles/toxicidad , Sustancias Luminiscentes/síntesis química , Sustancias Luminiscentes/toxicidad , Lisosomas/metabolismo , Microscopía Confocal , Mitocondrias/metabolismo , Proteolisis , Albúmina Sérica Bovina/toxicidadRESUMEN
A novel near infrared (NIR) phosphorescent osmium complex (Os1) was developed for lysosome tracking and photodynamic therapy. Owing to its NIR photophysical properties, cellular imaging ability and phototoxicity, it has advantages over its ruthenium analogue (Ru1).